Plus Therapeutics (PSTV)
Market Price (5/10/2026): $6.1 | Market Cap: $33.8 MilSector: Health Care | Industry: Biotechnology
Plus Therapeutics (PSTV)
Market Price (5/10/2026): $6.1Market Cap: $33.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -174% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -70% High stock price volatilityVol 12M is 2193% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% Key risksPSTV key risks include [1] a stated substantial doubt about its ability to continue as a going concern and [2] potential delisting from Nasdaq for non-compliance with listing requirements. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -174% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -15 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -70% |
| High stock price volatilityVol 12M is 2193% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% |
| Key risksPSTV key risks include [1] a stated substantial doubt about its ability to continue as a going concern and [2] potential delisting from Nasdaq for non-compliance with listing requirements. |
Qualitative Assessment
AI Analysis | Feedback
1. Plus Therapeutics reported a significant beat in its Fourth Quarter 2025 earnings. The company announced an Adjusted Earnings Per Share (EPS) of $6.25, substantially surpassing the analyst consensus estimate of a loss of $0.03. Additionally, quarterly revenue reached $1.37 million, exceeding analyst estimates of $1.23 million. This performance represents a 100% earnings surprise.
2. The company made notable advancements in its REYOBIQ clinical development program. Plus Therapeutics completed a Type B meeting with the U.S. Food and Drug Administration (FDA) on January 8, 2026, to discuss the pivotal trial strategy for REYOBIQ in leptomeningeal metastases (LM). The FDA also granted Orphan Drug Designation to REYOBIQ for the treatment of pediatric malignant gliomas on April 8, 2026. The company expects to report data from its ReSPECT-LM Phase 2 trial in the third quarter of 2026 and complete enrollment in its ReSPECT-GBM glioblastoma Phase 2 trial with data anticipated in the fourth quarter of 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The 7.3% change in PSTV stock from 1/31/2026 to 5/9/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.70 | 6.12 | 7.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 4 | 6 | -22.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/9/2026| Return | Correlation | |
|---|---|---|
| PSTV | 7.3% | |
| Market (SPY) | 3.6% | 1.9% |
| Sector (XLV) | -6.9% | -6.2% |
Fundamental Drivers
The -54.9% change in PSTV stock from 10/31/2025 to 5/9/2026 was primarily driven by a -22.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.57 | 6.12 | -54.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 4 | 6 | -22.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/9/2026| Return | Correlation | |
|---|---|---|
| PSTV | -54.9% | |
| Market (SPY) | 5.5% | 2.1% |
| Sector (XLV) | 0.3% | -5.5% |
Fundamental Drivers
The -66.0% change in PSTV stock from 4/30/2025 to 5/9/2026 was primarily driven by a -94.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.98 | 6.12 | -66.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 6 | -94.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/9/2026| Return | Correlation | |
|---|---|---|
| PSTV | -66.0% | |
| Market (SPY) | 30.4% | 1.5% |
| Sector (XLV) | 4.0% | -3.6% |
Fundamental Drivers
The -93.7% change in PSTV stock from 4/30/2023 to 5/9/2026 was primarily driven by a -98.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 97.42 | 6.12 | -93.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 6 | -98.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/9/2026| Return | Correlation | |
|---|---|---|
| PSTV | -93.7% | |
| Market (SPY) | 78.7% | 0.8% |
| Sector (XLV) | 13.0% | -2.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PSTV Return | -48% | -70% | -63% | -34% | -55% | -54% | -99% |
| Peers Return | 2% | 11% | 24% | -35% | -25% | 17% | -20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| PSTV Win Rate | 42% | 25% | 50% | 33% | 50% | 40% | |
| Peers Win Rate | 33% | 42% | 44% | 44% | 52% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| PSTV Max Drawdown | -49% | -71% | -79% | -43% | -84% | -99% | |
| Peers Max Drawdown | -28% | -41% | -27% | -54% | -51% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CATX, LNTH, CLRB, ATNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | PSTV | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.8% | -9.5% |
| % Gain to Breakeven | 126.0% | 10.5% |
| Time to Breakeven | 23 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -50.9% | -33.7% |
| % Gain to Breakeven | 103.8% | 50.9% |
| Time to Breakeven | 14 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -19.5% | -0.2% |
| % Gain to Breakeven | 24.3% | 0.2% |
| Time to Breakeven | 5 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -45.3% | -17.9% |
| % Gain to Breakeven | 82.9% | 21.8% |
| Time to Breakeven | 354 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -39.0% | -15.4% |
| % Gain to Breakeven | 63.9% | 18.2% |
| Time to Breakeven | 167 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -69.2% | -53.4% |
| % Gain to Breakeven | 224.4% | 114.4% |
| Time to Breakeven | 255 days | 1085 days |
In The Past
Plus Therapeutics's stock fell -55.8% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 126.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PSTV | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -55.8% | -9.5% |
| % Gain to Breakeven | 126.0% | 10.5% |
| Time to Breakeven | 23 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -50.9% | -33.7% |
| % Gain to Breakeven | 103.8% | 50.9% |
| Time to Breakeven | 14 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -45.3% | -17.9% |
| % Gain to Breakeven | 82.9% | 21.8% |
| Time to Breakeven | 354 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -39.0% | -15.4% |
| % Gain to Breakeven | 63.9% | 18.2% |
| Time to Breakeven | 167 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -69.2% | -53.4% |
| % Gain to Breakeven | 224.4% | 114.4% |
| Time to Breakeven | 255 days | 1085 days |
In The Past
Plus Therapeutics's stock fell -55.8% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 126.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Plus Therapeutics (PSTV)
AI Analysis | Feedback
Here are 1-3 brief analogies for Plus Therapeutics (PSTV):- Imagine a small, R&D-heavy Eli Lilly trying to engineer a breakthrough radioactive drug specifically for central nervous system (CNS) cancers.
- It's like a specialized, early-stage Genentech, but exclusively focused on developing novel radiation therapies for aggressive brain cancers.
- Think of a focused biotech startup aiming to do for brain cancer what an early Gilead Sciences did for HIV – tackle a devastating disease with a unique, high-impact therapy.
AI Analysis | Feedback
- Rhenium-186 NanoLiposome: A patented radiotherapy drug candidate in development for treating central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
AI Analysis | Feedback
Plus Therapeutics, Inc. (PSTV) is a clinical-stage pharmaceutical company focused on the development of treatments. Its lead drug candidate, Rhenium-186 NanoLiposome, is currently in clinical trials for central nervous system cancers.
Given its clinical-stage status, Plus Therapeutics does not currently have major commercial customers in the traditional sense, as its drug candidates are still under development and have not yet received regulatory approval for commercial sale. Therefore, the company does not primarily sell to other companies or directly to individuals. Its activities are focused on research, development, and clinical trials aimed at future commercialization.
AI Analysis | Feedback
nullAI Analysis | Feedback
Marc Hedrick, MD, MBA - President and CEO
Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. He previously held executive leadership roles, including President, CEO, and Director at Cytori Therapeutics, Inc., which was formerly known as Plus Therapeutics. Dr. Hedrick also served as President and CEO of StemSource, Inc. A trained general, vascular, and plastic surgeon, he was a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA), and Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Andrew Sims, CPA - Vice President and Chief Financial Officer
Mr. Andrew Sims serves as the Vice President and Chief Financial Officer of Plus Therapeutics, Inc. He previously held Chief Financial Officer roles at several private equity-backed companies, including Amplify LLC from 2012 to 2017 and Verbatim Support Services LLC from 2017 to 2019. His professional focus includes mergers and acquisitions, integrations, corporate capitalization, and building and managing teams for global growth. Before joining Plus Therapeutics, Mr. Sims was a Partner at Mazars, a global accounting and advisory firm, where he was the lead partner on over 50 acquisitions.
Russ Havranek, MS MBA - EVP, Commercial and Corporate Strategy
Russ Havranek is the Executive Vice President of Commercial and Corporate Strategy for Plus Therapeutics.
Russell Bradley - President and General Manager, CNSide Diagnostics
Russell Bradley serves as the President and General Manager of CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics. He brings over 30 years of leadership experience in diagnostics and life sciences, with previous senior executive roles at Abbott Laboratories, Luminex Corporation, and Beckman Coulter.
Daniel Ortega, MBA - VP, Development and Technical Operations
Daniel Ortega is the Vice President of Development and Technical Operations at Plus Therapeutics.
AI Analysis | Feedback
The key risks to Plus Therapeutics (PSTV) are:1. Clinical Trial and Regulatory Risks
As a clinical-stage pharmaceutical company, Plus Therapeutics' success hinges on the favorable outcomes of its ongoing clinical trials for Rhenium-186 NanoLiposome (186RNL) across indications such as recurrent glioblastoma (ReSPECT-GBM), leptomeningeal metastases (ReSPECT-LM), and pediatric brain cancers (ReSPECT-PBC). Any delays, failures, or adverse findings in these trials, or the inability to secure necessary regulatory approvals from bodies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), could significantly harm the company's business and prospects.
2. Financial Health and Funding Risks
Plus Therapeutics has a history of incurring net losses and negative cash flow from its operations and is expected to continue doing so for the foreseeable future. The company requires substantial additional funding to finance its product development activities, clinical trials, and general operations. Its ability to continue as a "going concern" is dependent on raising this additional capital and successfully executing its operational plans. Future financing efforts, which are frequently necessary, may lead to significant dilution of existing shareholders' investments.
3. Nasdaq Listing and Share Price Risks
Plus Therapeutics has faced challenges maintaining compliance with Nasdaq's listing standards, including requirements for minimum stockholders' equity. Receiving notices of non-compliance and the risk of delisting from Nasdaq pose a significant threat. Delisting would severely impair the liquidity of its common stock and negatively impact the company's ability to raise capital, further exacerbating its financial risks and potentially leading to a decline in its share price.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Plus Therapeutics' main products or services, which target central nervous system cancers, are as follows:
- Recurrent Glioblastoma: The global recurrent glioblastoma multiforme treatment market was valued at approximately USD 380.6 million in 2025. The top 7 markets (U.S., EU4, UK, and Japan) for recurrent glioblastoma are projected to grow at a Compound Annual Growth Rate (CAGR) of 6.06% from 2025 to 2035. The United States represents the largest market for this treatment.
- Leptomeningeal Metastases: The global market for leptomeningeal metastases management is valued at approximately USD 2.5 billion in 2024 and is expected to reach around USD 4.5 billion by 2034. The market in the 7MM (U.S., EU4, UK, and Japan) was approximately USD 1.7 billion in 2024. The United States accounts for the largest market size within the 7MM, representing 60% of it.
- Pediatric Brain Cancers: The global pediatric brain tumors market is estimated to be valued at USD 1.66 billion in 2025 and is projected to reach USD 2.68 billion by 2032, with a CAGR of 7.1% from 2025 to 2032. North America holds a dominant position in this market, accounting for approximately 40% of the global market share in 2023.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Plus Therapeutics (PSTV) over the next 2-3 years:- Advancement and Potential Commercialization of REYOBIQ for Leptomeningeal Metastases (LM): Plus Therapeutics is actively progressing its lead drug candidate, Rhenium-186 NanoLiposome (REYOBIQ), through clinical trials for leptomeningeal metastases (LM). The company plans to complete its Phase 1 LM trials and transition to later-stage trials in 2025. The FDA has already granted Orphan Drug Designation to REYOBIQ for the treatment of LM, which could facilitate its development and market access. Furthermore, Plus Therapeutics has reached an agreement with the FDA to initiate a Phase 1 multiple-dose administration trial for ReSPECT-LM, with site start-up currently underway. The company anticipates completing Phase 2 in 2025. This progression towards regulatory approval and eventual market launch represents a significant potential revenue stream addressing an unmet medical need.
- Launch and Commercialization of CNSide Diagnostic Test: Plus Therapeutics has acquired the assets necessary to exclusively commercialize CNSide, a novel diagnostic for leptomeningeal metastases. Positive topline results from the FORESEE trial for the CNSide diagnostic have been reported. The company is planning a limited launch of the CNSide diagnostic test in 2025 and is working towards CLIA compliance certification for its Houston-based clinical laboratory, which is crucial for the commercialization of this diagnostic tool. The CNSide platform is viewed as a feasible, clinically relevant, and scalable tool for managing leptomeningeal disease.
- Advancement of REYOBIQ for Pediatric Brain Cancers: Plus Therapeutics is developing REYOBIQ for pediatric brain cancers, including high-grade glioma and ependymoma. The company secured a $3 million grant from the U.S. Department of Defense to support a Phase 1 trial for these pediatric indications. An Investigational New Drug (IND) application for the ReSPECT-PBC pediatric brain cancer trial is under review, with ongoing interactions with the FDA towards final IND approval. The anticipated progression of this program lays the groundwork for future market entry and revenue generation in this specialized area.
- Continued Growth in Grant Revenue: As a clinical-stage company, grant revenue plays a crucial role in funding Plus Therapeutics' research and development efforts. The company reported $5.8 million in grant revenue in 2024, an increase from $4.9 million in 2023. For 2025, Plus Therapeutics expects grant revenue to be in the range of $6 million to $8 million, indicating a consistent and growing financial contribution that supports the advancement of its product pipeline towards commercialization. These grants primarily originate from sources such as the Cancer Prevention & Research Institute of Texas (CPRIT) and the U.S. Department of Defense.
AI Analysis | Feedback
Share Repurchases
- Plus Therapeutics announced an Equity Buyback for $0.5 million worth of its shares on November 4, 2023.
Share Issuance
- In March 2025, Plus Therapeutics completed an underwritten equity financing, raising approximately $15.0 million in gross proceeds.
- In June 2025, the company announced a comprehensive restructuring of its March 2025 equity financing to eliminate potential dilution of up to 1.5 billion shares of common stock, involving the cancellation of warrants and approximately 25 million shares of common stock.
- In August 2025, stockholders approved the potential issuance of up to $50.0 million of common stock to Lincoln Park Capital under a purchase agreement.
Inbound Investments
- Plus Therapeutics completed an underwritten equity financing, raising approximately $15.0 million in gross proceeds in March 2025.
- As of September 30, 2025, the company held $16.6 million in cash and investments, partially supported by non-dilutive funding, including a $1.9 million advance from a $17.6 million Cancer Prevention and Research Institute of Texas (CPRIT) grant.
- Grant revenue was $5.2 million for the year 2025, $5.8 million in 2024, and $4.9 million in 2023.
Capital Expenditures
- Plus Therapeutics Inc invested $27K in capital expenditures in Q3 2025.
- In the 12 months prior to a 2026 reporting date, capital expenditures were -$48,000.
- The company anticipates increased research and development expenditures in 2026 compared to 2025, focusing on the ReSPECT-LM clinical trial, manufacturing scale-up for REYOBIQ, and initial enrollments in the ReSPECT-PBC clinical trial, along with expanding CNSide research and development teams.
Trade Ideas
Select ideas related to PSTV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.76 |
| Mkt Cap | 0.0 |
| Rev LTM | 0 |
| Op Inc LTM | -23 |
| FCF LTM | -23 |
| FCF 3Y Avg | -32 |
| CFO LTM | -23 |
| CFO 3Y Avg | -32 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.6% |
| Rev Chg 3Y Avg | 15.4% |
| Rev Chg Q | 1.2% |
| QoQ Delta Rev Chg LTM | 0.1% |
| Op Inc Chg LTM | -4.1% |
| Op Inc Chg 3Y Avg | 6.0% |
| Op Mgn LTM | -14,164.0% |
| Op Mgn 3Y Avg | 27.7% |
| QoQ Delta Op Mgn LTM | 5,963.0% |
| CFO/Rev LTM | -12,695.7% |
| CFO/Rev 3Y Avg | 28.1% |
| FCF/Rev LTM | -12,698.0% |
| FCF/Rev 3Y Avg | 23.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | 229.3 |
| P/Op Inc | -1.6 |
| P/EBIT | -1.6 |
| P/E | -1.5 |
| P/CFO | -1.6 |
| Total Yield | -57.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -52.7% |
| D/E | 0.0 |
| Net D/E | -0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 14.3% |
| 3M Rtn | 2.0% |
| 6M Rtn | 4.0% |
| 12M Rtn | -11.5% |
| 3Y Rtn | -84.5% |
| 1M Excs Rtn | 5.9% |
| 3M Excs Rtn | -4.8% |
| 6M Excs Rtn | -11.1% |
| 12M Excs Rtn | -37.8% |
| 3Y Excs Rtn | -166.3% |
Price Behavior
| Market Price | $6.12 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/16/2000 | |
| Distance from 52W High | -72.5% | |
| 50 Days | 200 Days | |
| DMA Price | $5.56 | $10.99 |
| DMA Trend | down | down |
| Distance from DMA | 10.1% | -44.3% |
| 3M | 1YR | |
| Volatility | 4,413.4% | 2,202.0% |
| Downside Capture | 9.27 | 4.73 |
| Upside Capture | 1578.33 | 551.80 |
| Correlation (SPY) | 1.8% | 1.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -68.25 | 4.02 | 5.90 | 5.10 | 2.63 | 0.69 |
| Up Beta | -190.21 | -151.20 | -114.15 | -60.93 | -29.54 | -4.95 |
| Down Beta | 44.36 | 21.03 | 16.48 | 9.21 | 4.68 | 0.41 |
| Up Capture | 13884% | 11018% | 10765% | 6741% | 7001% | 420% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 20 | 32 | 60 | 115 | 343 |
| Down Capture | -2356% | 752% | 511% | 318% | 221% | 113% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 23 | 32 | 65 | 137 | 388 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PSTV | |
|---|---|---|---|---|
| PSTV | -56.7% | 2,193.2% | 0.97 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | -4.1% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 1.4% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | -6.6% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | 11.7% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 9.4% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | -2.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PSTV | |
|---|---|---|---|---|
| PSTV | -63.8% | 997.8% | 0.44 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | -1.0% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 1.4% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | -4.4% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 5.4% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 3.4% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | -0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PSTV | |
|---|---|---|---|---|
| PSTV | -69.6% | 715.7% | 0.28 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 1.3% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 2.9% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | -2.9% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 5.0% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 3.5% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 0.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/12/2026 | -15.2% | -18.2% | -26.6% |
| 10/30/2025 | 2.5% | -3.1% | 11.3% |
| 8/14/2025 | 15.8% | -10.9% | -23.8% |
| 3/27/2025 | -23.7% | -49.0% | -44.5% |
| 11/14/2024 | -7.1% | -4.8% | -7.1% |
| 8/14/2024 | -1.4% | 2.8% | 4.2% |
| 5/15/2024 | -3.0% | -6.0% | -13.8% |
| 3/5/2024 | -11.2% | -18.8% | -12.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 5 | 4 |
| # Negative | 14 | 14 | 15 |
| Median Positive | 3.9% | 5.2% | 25.3% |
| Median Negative | -6.5% | -12.7% | -16.7% |
| Max Positive | 15.8% | 39.3% | 41.2% |
| Max Negative | -23.7% | -49.0% | -44.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/30/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 10/31/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 04/20/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 10/20/2022 | 10-Q |
| 06/30/2022 | 07/21/2022 | 10-Q |
| 03/31/2022 | 04/21/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.